WebSep 7, 2024 · Gowen has been a member of Passage Bio’s board since February 2024 and currently serves on the Nominating and Corporate Governance Committee. ... be leading our board of directors following the unexpected passing of our former Chairman Dr. Tadataka Yamada,” said Bruce Goldsmith, Ph.D., president and chief executive officer (CEO), … WebMar 15, 2024 · “We are committed to our mission of developing transformative therapies for people with devastating CNS disorders,” said Bruce Goldsmith, Ph.D., president and chief executive officer, Passage Bio.
Bruce Goldsmith - Wikipedia
WebDec 17, 2024 · Passage Bio (NASDAQ: PASG) has leased about 62,000 square feet of lab space at the campus, which is intended to support analytics, process development, quality control and pilot manufacturing. WebJun 1, 2024 · Bruce Goldsmith, Ph.D. to step down as president and chief executive officer and member of board of directors, will serve as a strategic advisor for a transition period Edgar B. (Chip) Cale, current general counsel and corporate secretary, appointed as … form 35 appeal fees
Passage Bio Announces 2024 Research and Clinical
WebDr. Bruce A. Goldsmith is the Interim CEO at Civetta Therapeutics and Venture Partner at Deerfield Management. He joined Lycera as chief business officer in 2013 and brings more than 15 years of experience in the pharmaceutical and biotechnology industries. ... Passage Bio . Chief Executive Officer: Jan 2024: Jun 2024: Deepfield . Venture ... WebNov 6, 2024 · Passage Bio, Inc. (NASDAQ:PASG) Q3 2024 Results Conference Call November 4, 2024 8:30 AM ET. Company Participants. Stuart Henderson - VP, IR and … WebFeb 22, 2024 · Bruce Goldsmith, PhD, Passage Bio president and CEO. Passage Bio is doubling down on its lead clinical program, a gene therapy designed to treat GM1 … difference between ratchet and torque wrench